Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Schlumberger M, et al. Among authors: habra ma. N Engl J Med. 2015 Feb 12;372(7):621-30. doi: 10.1056/NEJMoa1406470. N Engl J Med. 2015. PMID: 25671254 Free article. Clinical Trial.
Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
Wirth LJ, Tahara M, Robinson B, Francis S, Brose MS, Habra MA, Newbold K, Kiyota N, Dutcus CE, Mathias E, Guo M, Sherman SI, Schlumberger M. Wirth LJ, et al. Among authors: habra ma. Cancer. 2018 Jun 1;124(11):2365-2372. doi: 10.1002/cncr.31344. Epub 2018 Apr 14. Cancer. 2018. PMID: 29656442 Free article. Clinical Trial.
Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib.
Taylor MH, Takahashi S, Capdevila J, Tahara M, Leboulleux S, Kiyota N, Dutcus CE, Xie R, Robinson B, Sherman S, Habra MA, Elisei R, Wirth LJ. Taylor MH, et al. Among authors: habra ma. Thyroid. 2021 Aug;31(8):1226-1234. doi: 10.1089/thy.2020.0779. Epub 2021 Apr 29. Thyroid. 2021. PMID: 33637020 Free PMC article. Clinical Trial.
Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid.
Tahara M, Schlumberger M, Elisei R, Habra MA, Kiyota N, Paschke R, Dutcus CE, Hihara T, McGrath S, Matijevic M, Kadowaki T, Funahashi Y, Sherman SI. Tahara M, et al. Among authors: habra ma. Eur J Cancer. 2017 Apr;75:213-221. doi: 10.1016/j.ejca.2017.01.013. Epub 2017 Feb 24. Eur J Cancer. 2017. PMID: 28237867 Free article. Clinical Trial.
The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring.
Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL. Carhill AA, et al. Among authors: habra ma. J Clin Endocrinol Metab. 2013 Jan;98(1):31-42. doi: 10.1210/jc.2012-2909. Epub 2012 Nov 26. J Clin Endocrinol Metab. 2013. PMID: 23185034 Free PMC article. Review.
Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME, Habra MA. Cabanillas ME, et al. Among authors: habra ma. Cancer Treat Rev. 2016 Jan;42:47-55. doi: 10.1016/j.ctrv.2015.11.003. Epub 2015 Dec 2. Cancer Treat Rev. 2016. PMID: 26678514 Free article. Review.
Parathyroid carcinoma: a 22-year experience.
Busaidy NL, Jimenez C, Habra MA, Schultz PN, El-Naggar AK, Clayman GL, Asper JA, Diaz EM Jr, Evans DB, Gagel RF, Garden A, Hoff AO, Lee JE, Morrison WH, Rosenthal DI, Sherman SI, Sturgis EM, Waguespack SG, Weber RS, Wirfel K, Vassilopoulou-Sellin R. Busaidy NL, et al. Among authors: habra ma. Head Neck. 2004 Aug;26(8):716-26. doi: 10.1002/hed.20049. Head Neck. 2004. PMID: 15287039
Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia.
Habra MA, Jimenez C, Huang SC, Cote GJ, Murphy WA Jr, Gagel RF, Hoff AO. Habra MA, et al. Endocr Pract. 2008 Dec;14(9):1108-14. doi: 10.4158/EP.14.9.1108. Endocr Pract. 2008. PMID: 19158050
Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma.
Xu JY, Murphy WA Jr, Milton DR, Jimenez C, Rao SN, Habra MA, Waguespack SG, Dadu R, Gagel RF, Ying AK, Cabanillas ME, Weitzman SP, Busaidy NL, Sellin RV, Grubbs E, Sherman SI, Hu MI. Xu JY, et al. Among authors: habra ma. J Clin Endocrinol Metab. 2016 Dec;101(12):4871-4877. doi: 10.1210/jc.2016-2815. Epub 2016 Sep 23. J Clin Endocrinol Metab. 2016. PMID: 27662441 Free PMC article.
Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.
Cote GJ, Evers C, Hu MI, Grubbs EG, Williams MD, Hai T, Duose DY, Houston MR, Bui JH, Mehrotra M, Waguespack SG, Busaidy NL, Cabanillas ME, Habra MA, Luthra R, Sherman SI. Cote GJ, et al. Among authors: habra ma. J Clin Endocrinol Metab. 2017 Sep 1;102(9):3591-3599. doi: 10.1210/jc.2017-01039. J Clin Endocrinol Metab. 2017. PMID: 28911154 Free PMC article.
126 results